Published in Geburtshilfe Frauenheilkd on May 01, 1993
E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res (1994) 4.51
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol (2001) 4.09
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Boerhaave's syndrome: analysis of the literature and report of 18 new cases. Dis Esophagus (1997) 3.06
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001) 2.91
Pylorus-preserving versus standard pancreatico-duodenectomy: an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg (1992) 2.54
Do we need better prognostic factors in node-negative breast cancer? Pro:. Eur J Cancer (2000) 2.28
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28
Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients. Aliment Pharmacol Ther (2013) 2.17
Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med (2001) 2.12
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg (2001) 2.04
Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer (1993) 2.01
Tracheobronchial lesions following oesophagectomy: prevalence, predisposing factors and outcome. Br J Surg (1998) 1.99
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat (1993) 1.97
Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol (1989) 1.81
Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg (1998) 1.78
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost (1997) 1.78
Number of lymph node metastases is significantly associated with survival in patients with radically resected carcinoma of the ampulla of Vater. Br J Surg (1995) 1.77
Pretherapeutic laparoscopic staging in advanced gastric carcinoma. Endoscopy (1999) 1.76
Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg (1994) 1.75
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Effect of attenuation correction on lesion detectability in FDG PET of breast cancer. J Nucl Med (1999) 1.70
Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry (2002) 1.70
Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg (1999) 1.69
Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography. Gastroenterology (1992) 1.68
Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun (1998) 1.64
Options in the management of esophageal perforation: analysis over a 12-year period. Dis Esophagus (2009) 1.63
Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol (1999) 1.61
Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus. Br J Surg (2000) 1.61
Stented versus nonstented pancreaticojejunostomy after pancreatoduodenectomy: a prospective study. Ann Surg (1999) 1.60
Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol (2000) 1.57
Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg (1999) 1.56
Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet (1994) 1.56
Achalasia and esophageal cancer: incidence, prevalence, and prognosis. World J Surg (2001) 1.55
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol (2003) 1.53
Endoscopic ultrasound in pancreatic tumor diagnosis. Gastrointest Endosc (1991) 1.52
[Comparison of the quality of life after subtotal and total gastrectomy for stomach carcinoma]. Dtsch Med Wochenschr (1996) 1.50
Free peritoneal tumour cells are an independent prognostic factor in curatively resected stage IB gastric carcinoma. Br J Surg (2006) 1.49
Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer (1998) 1.49
Enucleation of submucosal tumors of the esophagus: minimally invasive versus open approach. Surg Endosc (2004) 1.46
The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer (2007) 1.45
Cancer of the esophagogastric junction. Surg Oncol (2000) 1.45
An oral carcinogenicity and toxicity study of senna (Tinnevelly senna fruits) in the rat. Arch Toxicol (2005) 1.45
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res (1992) 1.44
Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun (1997) 1.44
New technique for temporary purse string suture in stapler anastomosis. Br J Surg (1990) 1.43
Early adenocarcinoma in Barrett's oesophagus. Br J Surg (1997) 1.42
Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer (2008) 1.42
A new concept in the surgical treatment of gastroesophageal reflux. Ann Surg (1983) 1.41
Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg (2000) 1.41
Failure of antireflux surgery: causes and management strategies. Am J Surg (1996) 1.40
Reconstruction of large palmar defects of the hand using free flaps. J Hand Surg Br (1997) 1.40
[Position paper on transplant surgery in visceral surgery]. Chirurg (1999) 1.38
Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet (2004) 1.38
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol (1994) 1.36
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res (1994) 1.36
Alkaline gastroesophageal reflux: assessment by ambulatory esophageal aspiration and pH monitoring. Am J Surg (1994) 1.35
[Cardia cancer: attempt at a therapeutically relevant classification]. Chirurg (1987) 1.35
MAGE-A gene expression pattern in primary breast cancer. Cancer Res (2001) 1.34
Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer (1993) 1.33
New developments in the treatment of gastric carcinoma. Semin Oncol (1990) 1.32
Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer (2006) 1.30
Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg (1999) 1.29
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem (1991) 1.29
Insights into adenovirus host cell interactions from structural studies. Virology (2008) 1.25
Prognostic factors of resected adenocarcinoma of the esophagus. Surgery (1995) 1.24
Three-dimensional pressure image and muscular structure of the human lower esophageal sphincter. Surgery (1995) 1.24
Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg (1997) 1.23
Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet (1989) 1.22
Free innervated latissimus dorsi muscle flap for reconstruction of full-thickness abdominal wall defects. Plast Reconstr Surg (1998) 1.22
Analysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer. Int J Cancer (1996) 1.22
Radical transhiatal esophagectomy with two-field lymphadenectomy and endodissection for distal esophageal adenocarcinoma. World J Surg (1997) 1.20
When is esophagitis healed? esophageal endoscopy, histology and function before and after cimetidine treatment. Dig Dis Sci (1982) 1.20
Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst (1996) 1.19
Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma. Cancer (1995) 1.19
Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med (1997) 1.18
Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol (2006) 1.18
Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management. Dysphagia (1993) 1.18
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol (2001) 1.16
Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br J Surg (2004) 1.15
Microsatellite instability in adenocarcinomas of the upper gastrointestinal tract. Relation to clinicopathological data and family history. Am J Pathol (1995) 1.15
Palliative treatment of malignant stenoses of the upper gastrointestinal tract using a combination of laser and afterloading therapy. Endoscopy (1986) 1.15
Prognostic factors in gastric stump carcinoma. Ann Surg (2000) 1.14
Role of endoscopic ultrasonography in gastric carcinoma. Endoscopy (1993) 1.13
Seroma as a common donor site morbidity after harvesting the latissimus dorsi flap: observations on cause and prevention. Ann Plast Surg (1997) 1.13
Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol (1996) 1.13
Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler (1992) 1.13
Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat (2008) 1.12
Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol (1994) 1.12
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer (2013) 1.12
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer (1994) 1.11
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer (1995) 1.11
Influence of hospital volume on local recurrence and survival in a population sample of rectal cancer patients. Eur J Surg Oncol (2005) 1.11